Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 48 min ago
Peer-reviewedCC BY 4.0Nutrients

Hydroxysafflor Yellow A Alleviates Diet-Induced Hepatic Steatosis Through Gut Microbiota Modulation and Suppression of STAT1/CD36 Signaling in Mice

  1. 1Key Laboratory of Endocrinology of National Health Commission, Department of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100730, China

Abstract

Background: Hydroxysafflor yellow A (HSYA) is the main active monomer of safflower yellow (SY), an adjunct for cardiovascular/cerebrovascular diseases. Our previous studies demonstrated that SY/HSYA improved non-alcoholic fatty liver disease (NAFLD) in obese mice; however, the precise mechanisms remain unclear. This study aimed to investigate the molecular targets and mechanisms by which HSYA ameliorates NAFLD. Methods: Male C57BL/6J mice were fed a high-fat diet for 8 weeks to induce diet-induced obesity (DIO), followed by HSYA treatment (100 mg/kg/d) for 8 weeks and antibiotic or non-antibiotic treatment for another 5 weeks. Body weight, OGTT, IPITT, liver histology, liver transcriptomics, and fecal metagenomics were assessed. In vitro, HepG2 cells were treated with 400 μM of palmitic acid (PA) to induce steatosis, followed by HSYA treatment and/or cluster of differentiation 36 (CD36) overexpression. Results: HSYA significantly reduced body weight and fat mass and improved glucose metabolism in DIO mice. HSYA also alleviated hepatic steatosis, which was partly abolished by antibiotic treatment, indicating partial dependence on gut microbiota. Metagenomics revealed that HSYA increased the abundance of Akkermansia muciniphila, which negatively correlated with NAFLD scores. HSYA significantly downregulated CD36 and its upstream signal transducer and activator of transcription 1 (STAT1) protein expression in liver tissue by 59.5% and 35.4%, respectively. Similarly, HSYA reduced CD36 and phospho-STAT1 expression in PA-treated HepG2 cells, and these effects were abolished by CD36 overexpression. Conclusions: HSYA improved NAFLD by remodeling gut microbiota and by inhibiting the STAT1/CD36 pathway, thereby reducing fatty acid uptake in hepatocytes.

Related

  1. P2226 alleviates respiratory inflammation and depression related behaviors with modulation of cytokines and gut microbiota in mice
    Hee-Seo Park, Hyo-Min Jang, Xiaoyang Ma +1
    Scientific ReportsPeer-reviewedCC BY-NC-ND 4.0Full textPhysiologyCrossref
  2. Surface-functionalized Bifidobacterium bifidum alleviates Clostridioides difficile infection by coordinating host immune modulation and gut microbiota restoration☆
    Hao Yang, Weibin Wu, Lamei Wang +7
    Gut MicrobesPeer-reviewedCC BY-NC 4.0Full textInfectious diseasePMC
  3. Hepatic Nnmt Deficiency Alleviates Thiamethoxam-Induced Hepatic Steatosis Via AMPK Activation
    Yilian Liu, Zixuan Meng, Siting Fan +2
    PhenomicsPeer-reviewedLicence not statedFull textPharmacology & toxicologyPMC
  4. Magnolol alleviates high-fat diet-induced steatosis, inflammation and fibrosis in obesity-associated liver injuries via MOGAT1-mediated lipid metabolism and NF-κB signaling
    Ziqing Huang, Zixia Huang, Linfei Luo +3
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Full textEpidemiology & public healthCrossrefEurope PMCPMC
  5. Canagliflozin Alleviates Experimental ANCA-Associated Vasculitis through Suppression of Pathogenic T-Cell Responses
    Xiang-Yu Han, Zhi-Ying Li, Su-Fang Chen +3
    Journal of the American Society of Nephrology : JASNPeer-reviewedLicence not statedFull textGeneral medicinePMC
BibTeX
@article{hu2026hydroxysafflor,
  title = {{Hydroxysafflor Yellow A Alleviates Diet-Induced Hepatic Steatosis Through Gut Microbiota Modulation and Suppression of STAT1/CD36 Signaling in Mice}},
  author = {Wenjing Hu and Xiaonan Guo and Ruizhen Hou and Yuchen Jiang and Yuxing Zhao and Linjie Wang and Hongbo Yang and Huijuan Zhu and Hui Pan and Fengying Gong},
  journal = {Nutrients},
  year = {2026},
  month = nov,
  doi = {10.3390/nu18223742},
  url = {https://www.mdpi.com/2072-6643/18/22/3742},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Hydroxysafflor Yellow A Alleviates Diet-Induced Hepatic Steatosis Through Gut Microbiota Modulation and Suppression of STAT1/CD36 Signaling in Mice
AU  - Wenjing Hu
AU  - Xiaonan Guo
AU  - Ruizhen Hou
AU  - Yuchen Jiang
AU  - Yuxing Zhao
AU  - Linjie Wang
AU  - Hongbo Yang
AU  - Huijuan Zhu
AU  - Hui Pan
AU  - Fengying Gong
PY  - 2026
DA  - 2026/11/11
JO  - Nutrients
DO  - 10.3390/nu18223742
UR  - https://www.mdpi.com/2072-6643/18/22/3742
AB  - Background: Hydroxysafflor yellow A (HSYA) is the main active monomer of safflower yellow (SY), an adjunct for cardiovascular/cerebrovascular diseases. Our previous studies demonstrated that SY/HSYA improved non-alcoholic fatty liver disease (NAFLD) in obese mice; however, the precise mechanisms remain unclear. This study aimed to investigate the molecular targets and mechanisms by which HSYA ameliorates NAFLD. Methods: Male C57BL/6J mice were fed a high-fat diet for 8 weeks to induce diet-induced obesity (DIO), followed by HSYA treatment (100 mg/kg/d) for 8 weeks and antibiotic or non-antibiotic treatment for another 5 weeks. Body weight, OGTT, IPITT, liver histology, liver transcriptomics, and fecal metagenomics were assessed. In vitro, HepG2 cells were treated with 400 μM of palmitic acid (PA) to induce steatosis, followed by HSYA treatment and/or cluster of differentiation 36 (CD36) overexpression. Results: HSYA significantly reduced body weight and fat mass and improved glucose metabolism in DIO mice. HSYA also alleviated hepatic steatosis, which was partly abolished by antibiotic treatment, indicating partial dependence on gut microbiota. Metagenomics revealed that HSYA increased the abundance of Akkermansia muciniphila, which negatively correlated with NAFLD scores. HSYA significantly downregulated CD36 and its upstream signal transducer and activator of transcription 1 (STAT1) protein expression in liver tissue by 59.5% and 35.4%, respectively. Similarly, HSYA reduced CD36 and phospho-STAT1 expression in PA-treated HepG2 cells, and these effects were abolished by CD36 overexpression. Conclusions: HSYA improved NAFLD by remodeling gut microbiota and by inhibiting the STAT1/CD36 pathway, thereby reducing fatty acid uptake in hepatocytes.
SN  - 2072-6643
ER  -